Prothena
CompanyIrelandFounded 2012
Prothena develops 9 assets, the furthest in phase 3 (birtamimab in light chain (al) amyloidosis). Mostly antibody acting on proteostasis, SNCA and TTR; based in Ireland, founded in 2012.
- 9
- Assets
- Furthest stage
- Phase 3
- 8
- Trials
- 0
- Signals
Pipeline
9Monoclonal antibody targeting cryptic epitope on misfolded light chain aggregates to promote clearance
Phase 3, Antibody, Proteostasis, light chain (al) amyloidosis
Monoclonal antibody targeting misfolded light chain aggregates to promote amyloid clearance
Phase 3, Antibody, Proteostasis, primary systemic (al) amyloidosis, AL amyloidosis (Phase 2)
Targets the C-terminus of alpha-synuclein.
Phase 3, Antibody, SNCA, Proteostasis, Parkinson's disease
6 more assets
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms4
- Trials9
- People22
- Signals1
- Integrity notices1
- Similar companies6